In collaboration with leading pharmaceutical companies, Becton Dickinson has introduced a next-generation glass prefillable syringe (PFS). Effivax’s design enhancements are focused on fill/finish and container reliability to help the company’s biopharmaceutical customers meet the stringent demands of vaccine manufacturing.
The syringe reduces the risk of line stoppage and improves total cost of ownership, manufacturing capacity, and supply availability.
“As biopharmaceutical companies continue to rapidly grow their vaccine pipelines, demand for PFS is accelerating across the globe — given their proven ability to facilitate faster administration, support dose sparing, and reduce vaccine waste,” says Eric Borin, worldwide president of BD Pharmaceutical Systems. “The launch of BD Effivax glass prefillable syringe strategically supports this growth and will create needed efficiencies in end-to-end production.”
Effivax will benefit from BD’s $1.2 billion, four-year investment announced in 2020 to expand and upgrade its manufacturing capacity and technology for PFS.